[go: up one dir, main page]

HRP20150194T1 - Upotreba rna za reprogramiranje somatskih stanica - Google Patents

Upotreba rna za reprogramiranje somatskih stanica Download PDF

Info

Publication number
HRP20150194T1
HRP20150194T1 HRP20150194TT HRP20150194T HRP20150194T1 HR P20150194 T1 HRP20150194 T1 HR P20150194T1 HR P20150194T T HRP20150194T T HR P20150194TT HR P20150194 T HRP20150194 T HR P20150194T HR P20150194 T1 HRP20150194 T1 HR P20150194T1
Authority
HR
Croatia
Prior art keywords
rna
cells
somatic cells
expression
fibroblasts
Prior art date
Application number
HRP20150194TT
Other languages
English (en)
Inventor
Ugur Sahin
Marco Poleganov
Tim Beissert
Original Assignee
Biontech Ag
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH filed Critical Biontech Ag
Publication of HRP20150194T1 publication Critical patent/HRP20150194T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Claims (7)

1. Postupak za proizvodnju stanica koje imaju svojstva matičnih stanica uključuje stupnjeve (i) dobivanje populacije stanica koje sadrže somatske stanice, (ii) uvođenje RNA u barem jedan dio navedenih somatskih stanica, navedeni RNA kodirajući čimbenici inducira razvoj svojstava matičnih stanica u navedenim somatskim stanicama, i (iii) dopuštajući razvoj stanica koje imaju obilježja matičnih stanica, naznačen time da se RNA dobiva in vitro transkripcijom ili kemijskom sintezom.
2. Postupak prema zahtjevu 1, naznačen time da je navedena RNA sposobna za ekspresiju OCT4 i sposobana za ekspresiju SOX2.
3. Postupak prema zahtjevu 2, naznačen time da postupak nadalje obuhvaća uvođenje RNA sposobne za ekspresiju NANOG i/ili RNA sposobne za ekspresiju LIN28.
4. Postupak prema zahtjevima 2 ili 3, naznačen time da postupak nadalje obuhvaća uvođenje RNA sposobne za ekspresiju KLF4 i/ili RNA sposobne za ekspresiju c-MYC.
5. Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da stanice koje imaju karakteristike matičnih stanica pokazuju pluripotentno stanje.
6. Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da su navedene somatske stanice fibroblasti, poželjno plućni fibroblasti, fibroblasti prepucija ili kožni fibroblasti.
7. Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time da se navedena RNA uvodi u navedeni najmanje jedan dio somatskih stanica elektroporacijom.
HRP20150194TT 2007-12-14 2015-02-19 Upotreba rna za reprogramiranje somatskih stanica HRP20150194T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07024312A EP2072618A1 (en) 2007-12-14 2007-12-14 Use of RNA for reprogramming somatic cells
PCT/EP2008/010593 WO2009077134A2 (en) 2007-12-14 2008-12-12 Use of rna for reprogramming somatic cells
EP08861423.5A EP2240572B1 (en) 2007-12-14 2008-12-12 Use of rna for reprogramming somatic cells

Publications (1)

Publication Number Publication Date
HRP20150194T1 true HRP20150194T1 (hr) 2015-06-05

Family

ID=39472686

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150194TT HRP20150194T1 (hr) 2007-12-14 2015-02-19 Upotreba rna za reprogramiranje somatskih stanica

Country Status (12)

Country Link
US (5) US20110065103A1 (hr)
EP (3) EP2072618A1 (hr)
JP (3) JP6231253B2 (hr)
CY (1) CY1116226T1 (hr)
DK (1) DK2240572T3 (hr)
ES (1) ES2532125T3 (hr)
HR (1) HRP20150194T1 (hr)
HU (1) HUE025698T2 (hr)
PL (1) PL2240572T3 (hr)
PT (1) PT2240572E (hr)
SI (1) SI2240572T1 (hr)
WO (1) WO2009077134A2 (hr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US8859229B2 (en) 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
EP3399025A1 (en) 2007-03-23 2018-11-07 Wisconsin Alumini Research Foundation Somatic cell reprogramming
EP2096169B1 (en) * 2007-10-31 2020-11-18 Kyoto University Nuclear reprogramming method
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
AU2009256202B2 (en) 2008-06-04 2014-07-03 FUJIFILM Cellular Dynamics, Inc. Methods for the production of IPS cells using non-viral approach
CA2734128A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International, Inc. Methods for the production of ips cells
WO2010048567A1 (en) * 2008-10-24 2010-04-29 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
EP2881461A1 (en) * 2008-11-21 2015-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
RU2399667C1 (ru) * 2009-04-10 2010-09-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения плюрипотентных клеток
EP2438159B1 (en) * 2009-05-29 2018-10-03 Kyoto University Method for selecting clone of induced pluripotent stem cells
AU2010254811B2 (en) 2009-06-05 2015-02-19 FUJIFILM Cellular Dynamics, Inc. Reprogramming T cells and hematopoietic cells
JP2011004674A (ja) * 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
EP3633025B1 (en) 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
PT3112467T (pt) 2009-12-07 2018-04-16 Univ Pennsylvania Preparações de arn compreendendo arn modificado purificado para a reprogramação de células
AU2015215938B2 (en) * 2009-12-07 2018-01-18 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
JP6039551B2 (ja) 2010-06-18 2016-12-07 セルラー ダイナミクス インターナショナル， インコーポレイテッド 透析された血清を有する心筋細胞培地
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3590949T (pt) 2010-10-01 2022-08-02 Modernatx Inc Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
WO2012072096A1 (en) * 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
WO2012096552A2 (ko) * 2011-01-14 2012-07-19 한국생명공학연구원 Ｒｅｘ１을 포함하는 세포 리프로그래밍 조성물 및 이를 이용한 유도 만능줄기세포 제조방법
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
WO2013078199A2 (en) * 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
KR20210134808A (ko) 2011-12-05 2021-11-10 팩터 바이오사이언스 인크. 세포를 형질감염시키는 방법들 및 생성물들
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
PL3421601T3 (pl) * 2011-12-30 2020-06-01 Cellscript, Llc Wytwarzanie i stosowanie zsyntetyzowanego in vitro ssRNA do wprowadzania do ssaczych komórek w celu indukcji efektu biologicznego lub biochemicznego
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2847329A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF CYTOPLASMA AND CYTOSCELETTE PROTEINS
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2852671T3 (pl) * 2012-05-21 2019-06-28 The Regents Of The University Of California Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
JP6510416B2 (ja) 2012-11-01 2019-05-08 ファクター バイオサイエンス インコーポレイテッド 細胞中でタンパク質を発現するための方法および生成物
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2787198T3 (es) 2014-01-31 2020-10-15 Factor Bioscience Inc ARN sintético para su uso en el tratamiento de la epidermólisis ampollosa distrófica
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
ES2810701T5 (es) 2015-10-05 2024-07-11 Modernatx Inc Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
EP3455346A1 (en) 2016-05-12 2019-03-20 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
HUE061077T2 (hu) 2016-05-18 2023-05-28 Modernatx Inc Interleukin-12 (IL12) kódoló polinukleotidok és felhasználásuk
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
KR102167826B1 (ko) * 2018-05-09 2020-10-20 주식회사 강스템바이오텍 Sox2, c-Myc를 이용하여 비신경 세포로부터 직접 리프로그래밍된 유도신경줄기세포를 제조하는 방법
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002300876A (ja) * 2001-04-03 2002-10-15 Nagoya Industrial Science Research Inst 組織を形成する細胞内で外来遺伝子を発現させる方法
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
WO2004063356A2 (en) * 2003-01-13 2004-07-29 Rao Mahendra S Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US7846731B2 (en) * 2003-10-08 2010-12-07 Kyoto University Method of introducing nucelic acid
WO2005056797A1 (en) * 2003-12-15 2005-06-23 Kye-Seong Kim Novel mirna molecules isolated from human embryonic stem cell
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
JP4731867B2 (ja) * 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
JP2007312782A (ja) * 2004-11-18 2007-12-06 Hiroshima Univ 遺伝子増幅により形成された反復配列から、発現抑制されているタンパク質を発現させる方法、キット、および形質転換体
EP1876233A1 (en) * 2005-01-24 2008-01-09 Japan Health Sciences Foundation Cells capable of differentiating into cardiac muscle cells
JP2008193897A (ja) * 2005-04-19 2008-08-28 Nara Institute Of Science & Technology 多能性幹細胞増殖促進剤
JP4685531B2 (ja) * 2005-07-11 2011-05-18 ローム株式会社 降圧型スイッチングレギュレータおよびその制御回路ならびにそれを用いた電子機器
JP2007082436A (ja) * 2005-09-20 2007-04-05 Bioinformatics Institute For Global Good Inc 機能性ＲＮＡが制御するターゲットｍＲＮＡの予測・同定方法及びその利用方法
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
BRPI0619794B8 (pt) * 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
EP1986667A1 (en) * 2006-02-22 2008-11-05 Argos Therapeutics, Inc. Dendritic cells transiently transfected with a membrane homing polypeptide and their use
US8859229B2 (en) 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
KR101532442B1 (ko) * 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법

Also Published As

Publication number Publication date
DK2240572T3 (en) 2015-03-09
US11008550B2 (en) 2021-05-18
JP2011505814A (ja) 2011-03-03
SI2240572T1 (sl) 2015-07-31
JP6648187B2 (ja) 2020-02-14
JP6231253B2 (ja) 2017-11-15
PL2240572T3 (pl) 2015-08-31
EP2896690A3 (en) 2015-08-19
CY1116226T1 (el) 2017-03-15
JP2018134102A (ja) 2018-08-30
ES2532125T3 (es) 2015-03-24
US20170218342A1 (en) 2017-08-03
JP2015198664A (ja) 2015-11-12
US20160122721A1 (en) 2016-05-05
EP2240572B1 (en) 2015-02-11
WO2009077134A3 (en) 2009-08-27
US20210324341A1 (en) 2021-10-21
PT2240572E (pt) 2015-04-07
WO2009077134A2 (en) 2009-06-25
EP2896690A2 (en) 2015-07-22
US20190194623A1 (en) 2019-06-27
HUE025698T2 (en) 2016-04-28
EP2240572A2 (en) 2010-10-20
EP2072618A1 (en) 2009-06-24
US20110065103A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
HRP20150194T1 (hr) Upotreba rna za reprogramiranje somatskih stanica
WO2009061442A8 (en) Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
RU2018112719A (ru) Способы и препараты для трансфекции клеток
JP2015506673A5 (hr)
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
EP2342333A4 (en) Method for producing induced pluripotent stem cells
HK1156976A1 (en) Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations
JP2015516812A5 (hr)
WO2010017562A3 (en) Induced pluripotent stem cells
EP2462225A4 (en) METHOD FOR EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS
WO2002078449A3 (en) Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
WO2011076422A8 (de) Lithiumdisilikat-glaskeramik, verfahren zu deren herstellung und deren verwendung
BRPI0507783A (pt) composição de tiol-éster processo para a produção de uma composição de tiol-éster, composição de hidroxi tiol-éster, processo para a produção de uma composição de hidróxi tiol-éster, composição de tiol-éster reticulada, processo para a produção de uma composição de tiol-éster reticulada, material fertilizante de liberação controlada e processo para produção do material fertilizante de liberação controlada
ATE533785T1 (de) Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine
SG178925A1 (en) Process for producing molecules containing specialized glycan structures
RU2014147093A (ru) Получение плюрипотентных клеток de novo
RU2012101874A (ru) Получение индуцированных плюрипотентных стволовых клеток из пуповинной крови
MX2022016474A (es) Composiciones y métodos para reprogramación celular usando arn circular.
EP2408904A4 (en) PREPARATION OF REPROGRAMMED PLURIPOTENTIAL CELLS
AU2012256014A8 (en) Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
EP2213746A4 (en) CELL FOR THE PREPARATION OF EXOGENEO PROTEIN AND MANUFACTURING PROCEDURE ON THE CELL
WO2010138873A8 (en) Long term expansion of human hematopoietic stem cells
CL2012003244A1 (es) Proceso para la produccion de parches o apositos de piel autologa mediante cultivo de queratinocitos y fibroblastos autologos con suero autologo para generacion; parche o apósito que comprende un sustrato de malla sobre la cual se ha colocado colágeno, encima queratinocitos y encima fibroblastos.
ATE375385T1 (de) Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
WO2011003406A3 (de) Mischung amphipathischer moleküle und verfahren zur zellmembranmodifikation durch fusion